The affected products are 10-millilter vials of testosterone injections with a strength of 200 milligrams/millileters. The recall, which is voluntary, was issued due to the presence of particulate matter in the vials.
The injections are used as a replacement therapy in males who are testosterone-deficient.
More articles on pharmacy:
Allergan sues Pfizer over costs related to opioid lawsuits
Teva’s revenue drops 18% in Q2
Who knew? There’s a trophy for ‘most hated’ pharma chief: 10 notes
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
